Disclosures for "High-precision Neurological Assessment Based on Digital Technology can Identify Relapsing Remitting Multiple Sclerosis Patients at Risk of Developing Secondary Progressive MS"
-
Dr. Hohweiller has nothing to disclose.
-
Mikael Cohen has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Biogen, Roche, Merck, Ad scientiam, Novartis, Alexion, BMS.
-
Jean-Phillippe Camdessanche has nothing to disclose.
-
Dr. Lebrun Frenay has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Revue Neurologique. The institution of Dr. Lebrun Frenay has received research support from FRANCE SEP.